Previous 10 | Next 10 |
2023-04-14 05:21:39 ET Summary Fusion Pharmaceuticals counts JNJ among its founding funders. They have an early stage pipeline of interesting targeted radiopharmaceuticals. Once they have data, I will probably be more interested. Fusion Pharmaceuticals ( FUSN ) d...
2023-04-12 16:22:13 ET Fusion Pharma ( NASDAQ: FUSN ) said it had received clearance for its investigational new drug ( IND ) applications for FPI-2068 and corresponding imaging analogue FPI-2107 to the U.S. Food and Drug Administration (FDA). Fusion is joi...
Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy Canada NewsWire FPI-2068 is a Bispecific Targeted Alpha Therapy (TAT) designed to Precisely Deliver Radiation to Tumor Cells HAMILTON, ON and BOSTON ...
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1 Canada NewsWire HAMILTON , ON and BOSTON , March 20, 2023 /CNW/ -- Fusion Pharmaceu...
2023-03-16 08:33:22 ET Fusion Pharmaceuticals press release ( NASDAQ: FUSN ): Q4 GAAP EPS of -$0.55. Revenue of $0.14M (-76.3% Y/Y). cash equivalents and investments of $186.6 million For further details see: Fusion Pharmaceuticals GAAP EPS of -$0.55, revenue...
Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates Canada NewsWire Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225 Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive...
Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference Canada NewsWire HAMILTON, ON and BOSTON , March 2, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generati...
A Canadian %Biotech company is turning heads this morning after it was announced that the company raised $60 million to fund the acquisition of a prostate cancer-targeted %Radiopharmaceutical from RadioMedix Inc. The release went on to say that %FusionPharmaceuticals ($FUSN) acqui...
Fusion Pharmaceuticals ( NASDAQ: FUSN ) has acquired the Investigational New Drug application for an alpha-emitting radiopharmaceutical for metastatic castrate-resistant prostate cancer asset in phase 2 from RadioMedix. The candidate, Ac-PSMA I&T, is a small molecule targetin...
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...